Johnson & Johnson

The Nano Biotechnology Market was valued at USD 5.65 billion in 2023 and is projected to reach USD 12.99 billion by 2032, growing at a CAGR of 9.71%. The market is driven by the increasing use of nanomaterials in pharmaceuticals, medical devices, and diagnostics, enhancing efficacy and precision. Key players include Ablynx, Nami Therapeutics, and Celgene Corporation. North America leads the market, with strong investments in R&D and advanced healthcare infrastructure.

The Multiple Myeloma Research Foundation (MMRF) announced the first patient enrollment in the Horizon Clinical Trials Program, an adaptive platform trial across the Multiple Myeloma Research Consortium (MMRC). The trial aims to determine optimal treatment combinations, sequences, and durations for critical patient populations, including those with relapsed and refractory myeloma.

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

Johnson & Johnson submits sBLAs to FDA for TREMFYA approval in children with moderate-to-severe plaque psoriasis and active juvenile psoriatic arthritis, based on Phase 3 studies and PK data extrapolation.

J&J submits sBLAs for guselkumab to treat moderate-to-severe plaque psoriasis in children aged 6+ and active juvenile psoriatic arthritis in children aged 5+. Submissions based on phase 3 studies and PK data, aiming to address treatment gaps in pediatric patients.

Intra-Cellular Therapies seeks FDA approval for Caplyta as an adjunct treatment for major depressive disorder (MDD), potentially expanding its market to over $1 billion. Caplyta, already approved for schizophrenia and bipolar disorder, saw Q3 sales of $175 million, with Q4 projections at least $193 million. The MDD submission is based on Phase III trials showing symptom improvement when paired with an antidepressant. Jefferies estimates a 90–95% approval likelihood, predicting a company valuation of $9–12 billion. Intra-Cellular is also exploring Caplyta for autism and developing ITI-214 for Parkinson’s and ITI-333 for opioid use.

Johnson & Johnson submitted two sBLAs for guselkumab, seeking FDA approval for pediatric indications: moderate to severe plaque psoriasis in children aged 6 and older, and active juvenile psoriatic arthritis in children aged 5 and older. Guselkumab selectively binds to the p19 subunit of IL-23, inhibiting its interaction with the IL-23 receptor, and has previously been approved for adult PsO and PsA.

Johnson & Johnson filed two sBLAs for Tremfya, seeking expanded use in pediatric patients with moderate-to-severe plaque psoriasis and active juvenile psoriatic arthritis. Tremfya, an IL-23 inhibitor, is already approved for adult patients with psoriasis and psoriatic arthritis. The filings are based on phase III studies and PK data. Tremfya sales grew 21.6% year-over-year to $2.7 billion in the first nine months of 2024. J&J expects Tremfya to reach $5 billion with approvals for inflammatory bowel disease conditions.

Johnson & Johnson seeks FDA approval for TREMFYA to treat moderate-to-severe plaque psoriasis in children aged 6+ and active juvenile psoriatic arthritis in children aged 5+. Submissions based on Phase III PROTOSTAR study and pharmacokinetic data from adult studies.

Chinese pharmaceutical and bio industry's technology exports surged to 80 cases in 2022, nearly doubling from 41 in 2021. Major deals include Merck's $9.475 billion investment in Kelun's ADC technology and J&J's CAR-T therapy 'Carvykti' developed with Legend Biotech. FDA approvals for Chinese drugs like Junshi Biosciences' 'Toripalimab' and Bio-Thera Solutions' 'Avitinib' highlight China's growing influence in global bio market.